Severe Aplastic Anemia
Conditions
Brief summary
The purpose of this study is to determine the feasibility of comparing outcomes of patients treated de novo with immunosuppressive therapy (IST) versus matched unrelated donor (MUD) hematopoietic stem cell transplant (HSCT) for pediatric acquired severe aplastic anemia.
Detailed description
A major challenge in treating pediatric Severe Aplastic Anemia (SAA) is the determination of best primary therapy for patients who lack a fully matched related donor for HSCT. Good survival outcomes have been seen with IST, but initial and late failures, CSA dependence, persistent cytopenias and secondary Myelodysplastic Syndrome (MDS) / Acute Myeloid Leukemia (AML) in a portion of patients leave considerable room for improvement. MUD HSCT survival in SAA has markedly improved, but a direct comparison of this approach with IST is necessary to determine whether this approach is feasible and will lead to better Event Free Survival. This trial will address the feasibility of randomization, test whether patients can be evaluated in a timely fashion and safely begin therapy with MUD HSCT or IST, and give a preliminary assessment of the safety of up-front MUD HSCT. If successful, this trial will lead to a future prospective trial comparing directly IST to MUD HSCT in this disease.
Interventions
rabbit anti-thymocyte globulin (ATG)
DRUGmethotrexate
methotrexate
DRUGfludarabine
fludarabine
DRUGcyclophosphamide
cyclophosphamide
low-dose total body irradiation (TBI)
PROCEDUREImmunosuppressive Therapy (IST)
Immunosuppressive Therapy (IST)
DRUGcyclosporine
cyclosporine
PROCEDUREMatched Unrelated Donor Hematopoietic Stem Cell Transplant
Matched Unrelated Donor (MUD) Hematopoietic Stem Cell Transplantation (HSCT)
horse anti-thymocyte globulin (ATG)
Sponsors
Michael Pulsipher
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
No minimum to 25 Years
Healthy volunteers
No
Inclusion criteria
1. Confirmed diagnosis of idiopathic SAA, defined as: * Bone marrow cellularity \<25%, or \<30% hematopoietic cells. * Two out of three of the following (in peripheral blood): neutrophils \<0.5 x109/L, platelets \<20 x109/L, reticulocyte count \<60 x109/L with hemoglobin \<8g/dL. 2. Age ≤25 years old. 3. No suitable fully matched related donor available (minimum 6/6 match for Human Leukocyte antigen (HLA) -A and B at intermediate or high resolution and DRB1 at high resolution using DNA based typing). 4. At least two unrelated donors noted on National Marrow Donor Program (NMDP) search who are well matched (9/10 or 10/10 for HLA-A, B, C, DRB1, and DQB1 using high resolution). 5. Signed informed consent for the randomized trial by patient and/or legal guardian. 6. Adequate organ function defined as in the judgment of the investigator, there is not irreversible organ damage that would preclude the patient from meeting the organ function inclusion criteria for HSCT listed in section 2.3.4 by the intended time of HSCT (6-8 weeks after randomization) or preclude patients from receiving horse ATG.
Exclusion criteria
1. Inherited bone marrow failure syndromes (IBMFS). The diagnosis of Fanconi anemia must be excluded by diepoxybutane (DEB) or equivalent testing on peripheral blood or marrow. Telomere length testing should be sent on all patients to exclude Dyskeratosis congenita, but if results are delayed or unavailable and there are no clinical manifestations of DC, patients may enroll. If patients have clinical characteristics suspicious for Shwachman Diamond syndrome, this syndrome must be excluded by pancreatic isoamylase testing or gene mutation analysis. Note: pancreatic isoamylase testing is not accurate in children less than 3 years. 2. Clonal cytogenetic abnormalities or fluorescence In Situ Hybridization (FISH) pattern consistent with pre-myelodysplastic syndrome (pre-MDS) or MDS on marrow examination (see section 4.2.3.1 for details of the required MDS FISH panel). 3. Known severe allergy to horse ATG. 4. Prior allogeneic stem cell transplant. 5. Prior solid organ transplant. 6. Infection with human immunodeficiency virus (HIV). 7. Active Hepatitis B or C. This should be excluded in patients where there is clinical suspicion of hepatitis (e.g. elevated LFTs). 8. Female patients who are pregnant or breast-feeding. 9. Prior malignancies except resected basal cell carcinoma or treated cervical carcinoma in situ.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of patients randomized to HSCT that actually complete HSCT | 4 years | Feasibility of comparing outcomes of patients treated de novo with IST versus matched unrelated donor HSCT for pediatric acquired severe aplastic anemia as defined by percentage of patients randomized to HSCT that actually complete HSCT. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Rates of secondary MDS or AML in both treatment arms. | 4 years | Rates of secondary MDS or AML in both treatment arms. |
| Rates of grade II-IV and III-IV acute GVHD, and extensive chronic GVHD in the MUD HSCT arm | 4 years | Rates of grade II-IV and III-IV acute GVHD, and extensive chronic GVHD in the MUD HSCT arm |
| Time from randomization to cessation of immune suppression recovery in both arms | 4 years | Time from randomization to cessation of immune suppression recovery in both arms |
| Rates of primary and secondary graft rejection in the MUD HSCT arm | 4 years | Rates of primary and secondary graft rejection in the MUD HSCT arm |
| Time from screening consent to randomization | 4 years | To measure the time from screening consent and randomization of patients to initiation of the preparative regimen of those randomized to HSCT. |
| Number of patients that fail to receive their primary assigned therapy (HSCT or IST). | 4 years | Number of patients fail to receive their primary assigned therapy (HSCT or IST). |
| Reasons why patients fail to receive their primary assigned therapy (HSCT or IST). | 4 years | Reasons why patients fail to receive their primary assigned therapy (HSCT or IST). |
| Treatment-related mortality at one year from randomization in both arms | 1 Year | Number of deaths that are treatment related |
| Rates of IST relapse | 4 years | Rates of IST relapse |
| Time from randomization to neutrophil recovery in both arms | 4 years | Time from randomization to neutrophil recovery in both arms |
| Time from randomization to platelet recovery in both arms | 4 years | Time from randomization to platelet recovery in both arms |
| Time from randomization to red blood cell recovery in both arms | 4 years | Time from randomization to red blood cell recovery in both arms |
| Rates of IST response | 4 years | Rates of IST response |
| Rates of other secondary malignancies in both treatment arms. | 4 years | Rates of other secondary malignancies in both treatment arms. |
| Development of symptomatic PNH in both treatment arms. | 4 years | Development of symptomatic PNH in both treatment arms. |
| Incidence of significant infection in both treatment arms | 4 years | Incidence of significant infection in both treatment arms |
| Time to immune reconstitution in the HSCT arm | 4 years | Time to immune reconstitution in the HSCT arm |
| Overall Survival at one year from randomization in both arms | 1 Year | percentage of enrolled patients living at 1 year post randomization |
Countries
United States
Outcome results
None listed